Home › Funds › ORBIMED ADVISORS LLC › RYTM
ORBIMED ADVISORS LLC position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
ORBIMED ADVISORS LLC reported holding 322,900 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$35.9M, representing 0.72% of its reported portfolio and ranking #38 among its reported holdings. ORBIMED ADVISORS LLC has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's RYTM position evolved
ORBIMED ADVISORS LLC first disclosed a stake in RYTM in Q3 2023 at 583,642 shares (US$13.4M). The position peaked in Q2 2026 at 322,900 shares, worth US$35.9M. Across 12 filings, ORBIMED ADVISORS LLC increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 322,900 shares valued at US$35.9M — an increase of 8,800 shares quarter over quarter.. Notable position changes include a 31% increase in Q1 2024 (shares fell 5% over the following quarter), a 38% trim in Q3 2024 (shares rose 7% over the following quarter), a 35% trim in Q2 2025 (shares rose 60% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 583.64K | $13.38M | New |
| Q4 2023 | 536.64K | $24.67M | Reduce |
| Q1 2024 | 704.84K | $30.54M | Add |
| Q2 2024 | 704.84K | $28.94M | Hold |
| Q3 2024 | 435.90K | $22.84M | Reduce |
| Q4 2024 | 400.00K | $22.39M | Reduce |
| Q1 2025 | 380.00K | $20.13M | Reduce |
| Q2 2025 | 248.51K | $15.70M | Reduce |
| Q3 2025 | 215.15K | $21.73M | Reduce |
| Q4 2025 | 239.80K | $25.67M | Add |
| Q1 2026 | 314.10K | $27.32M | Add |
| Q2 2026 | 322.90K | $35.85M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 52 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $622.27M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.21M sh · $245.22M · Q2 2026
- Polar Capital Holdings Plc 1.66M sh · $184.71M · Q2 2026
- Checkpoint Capital L.P. 1.19M sh · $131.68M · Q2 2026
- Siren, L.L.C. 1.14M sh · $126.16M · Q2 2026
- Rock Springs Capital Management LP 692.60K sh · $76.90M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $61.07M · Q2 2026
- Sofinnova Investments, Inc. 408.03K sh · $45.30M · Q2 2026
- BRAIDWELL LP 381.13K sh · $42.32M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held RYTM?
ORBIMED ADVISORS LLC has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ORBIMED ADVISORS LLC's current position in RYTM?
As of Q2 2026, ORBIMED ADVISORS LLC holds 322.90K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $35.85M, representing 0.72% of its reported portfolio and ranking #38.
Has ORBIMED ADVISORS LLC been buying or selling RYTM?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in RYTM. The position peaked in Q2 2026 at 322.90K shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.